Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF20A | O95235 | 12/20 | 0.69 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | CLK1 | P49759 | 7/20 | 0.55 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.55 |
| ▸ | CLK2 | P49760 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858032 | 1.00 | KIF20A (0.69) | KIF20ADYRK1AMEN1KMT2ANPC1 | |
| SCHEMBL2726006 | 0.84 | KIF20A (0.77) | KIF20ADYRK1AMEN1KMT2ANPC1 | |
| SCHEMBL2726001 | 0.84 | KIF20A (0.77) | KIF20ADYRK1AMEN1KMT2ANPC1 | |
| SCHEMBL2725529 | 0.81 | KIF20A (1.00) | KIF20ADYRK1AMEN1KMT2ANPC1 | |
| SCHEMBL29382113 | 0.81 | KIF20A (1.00) | KIF20ADYRK1AMEN1KMT2ANPC1 | |
| SCHEMBL2725764 | 0.81 | KIF20A (1.00) | KIF20ADYRK1AMEN1KMT2ANPC1 | |
| SCHEMBL2725524 | 0.81 | KIF20A (1.00) | KIF20ADYRK1AMEN1KMT2ANPC1 | |
| SCHEMBL274836 | 0.79 | KIF20A (0.79) | KIF20ADYRK1AMEN1KMT2ANPC1 | |
| SCHEMBL274837 | 0.79 | KIF20A (0.79) | KIF20ADYRK1AMEN1KMT2ANPC1 | |
| SCHEMBL21578427 | 0.77 | PIP4K2A (0.79) | KIF20ADYRK1AMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | KIF20A 871/4885DYRK1A 1054/4885MEN1 1169/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | KIF20A 871/4885DYRK1A 1054/4885MEN1 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.